The growth of the EPS is critical in understanding the current valuation of Agenus. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -15.70% over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Agenus is making for it’s investors or shareholders.
Agenus trades as part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Garo H Armen. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer.
Previous Intraday Performance:
The AGEN shares had a previous change of 2.05% which opened at 3.39 and closed at 3.49. It moved to an intraday high of 3.52 and a low of 3.38.
Over the last five trading days, AGEN shares returned -2.24% and in the past 30 trading days it returned 46.03%. Over three months, it changed 81.77%. In one year it has changed -7.92% and within that year its 52-week high was 6.19 and its 52-week low was 1.54. AGEN stock is 126.62% above its 52 Week Low.
Our calculations result in a 200 day moving average of 2.51 and a 50 day moving average of 2.90. Right now, AGEN stock is trading 39.01% above its 200 day moving average.
The company has a market cap of $457.6m with 131.1m shares outstanding and a float of 123.4m shares. Trading volume was 1,399,962 shares and has experienced an average volume of 2,084,852 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Agenus was -1.22 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.28.
Below was the last reported quarterly earnings per share:
Base on our calculations, the intrinsic value per share is 1.14, which means it might overvalued by -207.13%
Indicators Also to Watch:
Based on the latest filings, there is 41.00% of institutional ownership.
I calculated the beta to be 2.12
Based on last reported financials, the company’s return on assets is -105.80%, price-to-sales is 14.78 and price-to-book is 49.72.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
1 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
0 : Overall Result